Clover Health Investments Corp
NASDAQ:CLOV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (0.5), the stock would be worth $1.97 (21% downside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.7 | $2.5 |
0%
|
| 3-Year Average | 0.5 | $1.97 |
-21%
|
| 5-Year Average | 0.6 | $2.24 |
-10%
|
| Industry Average | 1.7 | $6.47 |
+159%
|
| Country Average | 2.4 | $9.03 |
+261%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$1B
|
/ |
Jan 2026
$1.9B
|
= |
|
|
$1B
|
/ |
Dec 2026
$2.9B
|
= |
|
|
$1B
|
/ |
Dec 2027
$3.4B
|
= |
|
|
$1B
|
/ |
Dec 2028
$3.8B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Clover Health Investments Corp
NASDAQ:CLOV
|
1.3B USD | 0.7 | -15.2 | |
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
320.2B USD | 0.7 | 26.6 | |
| US |
A
|
Anthem Inc
LSE:0HG8
|
85.8B USD | 0.4 | 15.2 | |
| US |
|
Elevance Health Inc
NYSE:ELV
|
72.4B USD | 0.4 | 12.8 | |
| US |
|
Humana Inc
NYSE:HUM
|
26.2B USD | 0.2 | 22.1 | |
| US |
|
Centene Corp
NYSE:CNC
|
19.1B USD | 0.1 | -2.9 | |
| US |
|
Molina Healthcare Inc
NYSE:MOH
|
7.8B USD | 0.2 | 16.5 | |
| US |
|
Healthequity Inc
NASDAQ:HQY
|
7B USD | 5.4 | 32.7 | |
| US |
M
|
Magellan Health Inc
F:MAH1
|
2.2B EUR | 0.5 | 8.5 | |
| BR |
|
Odontoprev SA
BOVESPA:ODPV3
|
8.5B BRL | 3.5 | 14.4 | |
| US |
|
Progyny Inc
NASDAQ:PGNY
|
1.5B USD | 1.1 | 25.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
Clover Health Investments Corp
Glance View
Clover Health Investments Corp. embarked on a mission to transform the healthcare landscape with its innovative approach as a next-generation Medicare Advantage insurer. Born out of the need to reduce inefficiencies and enhance care, Clover Health uses its proprietary technology platform, the Clover Assistant, to arm physicians with data-driven insights that facilitate informed decision-making at the point of care. By integrating technology with healthcare delivery, Clover targets not only the evident administrative wastage but also addresses the structural challenges faced by patients and providers alike. This unique integration of digital tools with a traditional insurance model sets Clover apart in an industry ripe for disruption. Revenue for Clover Health primarily comes from Medicare Advantage premiums, where it competes by offering cost-effective plans combined with improved service. The company augments its financial model through government reimbursements tied to patient outcomes and the quality of care. Central to this strategy is the effective use of data analytics to manage patient care, reduce medical costs, and improve customer satisfaction. This alignment of financial incentives—lowering costs while enhancing patient outcomes—fuels Clover’s growth narrative, positioning it as a key player in reshaping how Medicare Advantage operates at the intersection of technology and healthcare delivery.